Medical sector’s CRISPR Therapeutics’s (NASDAQ:CRSP) Buy rating Reiterated by Chardan Capital – 5 stars

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its Buy rating Reiterated by analysts at Chardan Capital – 5 stars in a research report issued to clients and investors. A price-to-earnings ratio of 18.94, market cap of 7.4B and a beta of 2.26.  CRISPR Therapeutics has a twelve month low $84.38 of  and a twelve month high of $220.20.

Shares of CRISPR Therapeutics traded down -$5.82 on Wednesday, reaching $96.77. 28,793 shares of the stock traded hands, compared to its average volume of 1127566. Shares of CRISPR Therapeutics at close on Wednesday were at $96.77. The firm’s 50 day moving average is $$118.80 and its 200 day moving average is $131.51.CRISPR Therapeutics  has a 12 month low of $92.33 and a 12 month high of $220.20. While on yearly highs and lows, CRISPR Therapeutics’s today has traded high as $98.33 and has touched $92.33 on the downward trend. See More Analyst Rating at: RATING

CRISPR Therapeutics (NASDAQ:CRSP) Moving Average Technical Analysis

5 day Moving Average is $100.33 And 5 day price change is -$5.22 (-5.12%)  with average volume for 5 day average is 2,922,800. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $110.13 and 20 day price change is -$20.49 (-17.47%) and average 20 day moving volume is 1,530,615. 50 day moving average is $118.80  and 50 day price change is -$24.65 ( -20.30%)  and with average volume for 50 days is : 1,231,136. 200 day moving average is $131.51  and 200 day price change is -$72.16 (-42.72%)  and with average volume for 200 days is : 1,651,566.

See More Analyst Rating at: RATING

CRISPR Therapeutics Earnings and What to expect: 

CRISPR Therapeutics last posted its quarterly earnings results on July 29th, 2021. The reported $9.44 earnings per share for the quarter, beating the consensus estimate of $3.52 by $5.92. The firm earned $900.70 million during the quarter, compared to analyst estimates of $678.05 million. CRISPR Therapeutics has generated ($5.29) earnings per share over the last year ($5.11 diluted earnings per share) and currently has a price-to-earnings ratio of 18.9. Earnings for CRISPR Therapeutics are expected to decrease in the coming year, from $4.81 to ($7.24) per share. CRISPR Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, October 27th, 2021 based off prior year’s report dates.

Earnings for CRISPR Therapeutics are expected to decrease in the coming year, from $4.81 to ($7.24) per share. The P/E ratio of CRISPR Therapeutics is 18.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.72. The P/E ratio of CRISPR Therapeutics is 18.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 32.17. CRISPR Therapeutics has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Other owners latest trading in CRSP :

  • On 10/13/2021 shares held by Foundations Investment Advisors LLC were 4,041 which equates to market value of $0.41M and appx 0.00% owners of CRSP
  • On 10/12/2021 shares held by Green Alpha Advisors LLC were 14,922 which equates to market value of $1.67M and appx 1.20% owners of CRSP
  • On 10/12/2021 shares held by Harbor Investment Advisory LLC were 16,074 which equates to market value of $1.80M and appx 0.20% owners of CRSP
  • In total Institutional ownership equates to Institutional Ownership Percentage: 52.68% for CRSP

See More Analyst Rating at: RATING